NCT06669611 Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
| NCT ID | NCT06669611 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sun Yat-sen University |
| Condition | Nasopharyngeal Cancinoma (NPC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 242 participants |
| Start Date | 2024-11-27 |
| Primary Completion | 2027-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 242 participants in total. It began in 2024-11-27 with a primary completion date of 2027-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.
Eligibility Criteria
Inclusion Criteria: 1. Age over 18 years. 2. ECOG score of 0-1. 3. Expected survival of at least 12 weeks. 4. Recurrent/Metastatic Nasopharyngeal Carcinoma. 5. At least 4 weeks since the previous chemotherapy. 6. At least one (according to RECIST) measurable lesion, lesions that have been previously irradiated can not be considered target lesions. 7. had adequate organ function
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06669611 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nasopharyngeal Cancinoma (NPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06669611 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 242 participants.
Is NCT06669611 currently recruiting?
Yes, NCT06669611 is actively recruiting participants. Contact the research team at xiangyq@sysucc.org.cn for enrollment information.
Where is the NCT06669611 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06669611 clinical trial?
NCT06669611 is sponsored by Sun Yat-sen University. The trial plans to enroll 242 participants.